The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...

Selecta Biosciences is jumping into Cartesian’s cell therapy cockpit, preparing to take flight once again after landing nearly all of its previous programs. The two companies announced a reverse ...

Astellas is putting the kibosh on a licensing deal with Cartesian Therapeutics, deciding it’s no longer interested in using the latter’s Xork asset to help treat Pompe disease. The decision disclosed ...

NEW YORK, May 05, 2025--(BUSINESS WIRE)--Cartesian Growth Corporation III (the "Company") announced today the closing of its initial public offering of 27,600,000 units, including 3,600,000 units ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation (“Cartesian”) (NASDAQ: GLBL), a publicly traded special purpose acquisition company, announced today that in an extraordinary general meeting on ...

FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

Density describes substances based on much mass they have in a certain volume. Increasing pressure causes a gas to decrease in volume while it’s mass stays the same. Objects that are more dense than ...

Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...